Glypican-3 (GPC3) has emerged as a promising immunotherapeutic target for hepatocellular carcinoma (HCC). However, its ...

Preserved liver function and absence of metabolic dysfunction-associated steatotic liver disease or varices were associated with longer survival.

Liver cancer continues to be one of the deadliest and increasingly common cancers worldwide. Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide. Despite ...

By a News Reporter-Staff News Editor at Insurance Daily News-- Current study results on Oncology- Liver Cancer have been published. According to news originating from Busan, South Korea, by NewsRx ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and ...

Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide, largely due to the limited efficacy of ...

Immunotherapy-based combinations appear to provide greater benefit than multi-kinase inhibitors for these patients.

A Memphis teen who has already endured unimaginable health challenges got to celebrate her quinceañera as planned this summer ...

One patient has glioblastoma multiforme (GBM), and the other patient has advanced hepatocellular carcinoma (HCC) treated in the second line. Neither patient has experienced PIC-related adverse events ...

MASLD and Liver Cancer: What’s the Link? Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition where too much fat builds up in your liver. Unlike fatty liver caused by heavy ...